[French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].
During the last decades, long-term prophylaxis has become the gold standard for the treatment of children with severe haemophilia A or B. Prophylactic replacement regimens modify the natural history of the disease by aiming at the prevention of haemarthrosis, target joints and arthropathy. This treatment represents a constraint and an enhanced exposure to anti-haemophilic concentrates, which means potential increase of related risks and significant additional cost. The context of crisis of confidence due to the blood borne infections in the 1980s, may have delayed prophylaxis as an universal gold standard.In the early 2000s, the French group CoMETH proposed recommendations based on the review of the international experience. At first, specific guidelines of long-term prophylaxis were dedicated to children with severe haemophilia A or B, aged 3 years or less, with no history of target joint or arthropathy. The main concerns of this regimen consist in the early start and the escalating intensification of the treatment. In the French haemophilia care centres, the diffusion of these guidelines has apparently induced a significant turning point in therapeutic practices for haemophilia children. In 2006, more comprehensive recommendations were diffused to take into account all the children with severe haemophilia, whatever the bleeding history and joint status. The analysis of their impact, jointly with the National cohort "France Coag Network", will first assess the widespread implementation of the recommendations and the observance of the prophylactic regimen and identify factors associated to the compliance.
Meunier
S
S
Unité d'Hémostase Clinique, Groupement Hospitalier Edouard-Herriot, CRMH, Centre Régional de Traitement de l'Hémophilie, Hôpital Edouard-Herriot, CHRU, Place d'Arsonval, 69437 Lyon 03, France. sandrine.meunier@chu-lyon.fr
Trossaërt
M
M
Berger
C
C
Borel-Derlon
A
A
Dirat
G
G
Donadel-Claeyssens
S
S
Assolant
A Durin
AD
Guérois
C
C
Lutz
P
P
Rafowicz
A
A
Rothschild
C
C
Chambost
H
H
D002675:Child, Preschool; D003029:Coagulants / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005602:France; D006395:Hemarthrosis / Q000517:prevention & control*; D006467:Hemophilia A / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002836:Hemophilia B / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003029:Coagulants; D005169:Factor VIII